Tempus AI (TEM): Initiation of Coverage (FY2023-FY2025)
Key Points
- Explosive Revenue Growth: Revenue surged from $531.8M in FY2023 to $1,271.8M in FY2025 (+83% YoY), driven by Diagnostics scale-up (notably Ambry Genetics acquisition) and robust Data & Applications expansion.
- Diagnostics Dominance: Diagnostics revenue more than doubled to $955.4M in FY2025; test volumes tripled to 801,000, with hereditary tests (Ambry) contributing 460,500 units.
- Data & Applications Momentum: Segment revenue grew 31% YoY to $316.4M in FY2025, supported by large pharma contracts (AstraZeneca, GSK, Recursion) and new AI-driven offerings.
- Profitability Progress: Net loss narrowed sharply to $245.0M in FY2025 (from $705.8M in FY2024); adjusted EBITDA improved to -$7.4M (from -$104.7M).
- Strategic Moves: Major acquisitions (Ambry Genetics, Paige.AI, Deep 6 AI), international expansion (SB Tempus JV in Japan), and capital raises ($750M convertible notes, $195.5M ATM equity).
- Risks: Still unprofitable, heavy reliance on Diagnostics, customer concentration in Data & Applications, reimbursement/regulatory uncertainty, integration risk.
Business Overview
Tempus AI Inc. is a healthcare technology company focused on precision medicine through AI/ML-enabled diagnostics and data analytics. The business operates two main segments:
- Diagnostics: Next-generation sequencing (NGS), PCR profiling, molecular genotyping, and pathology testing, primarily in oncology and hereditary disease.
- Data & Applications: Monetization of de-identified patient data, AI-driven clinical trial matching, analytics, and algorithmic diagnostics for pharma and biotech clients.
Financial Snapshot: Fiscal Years (FY2023-FY2025)
| Fiscal Year | Revenue ($M) | Revenue Growth (%) | Diagnostics Revenue ($M) | Data & Apps Revenue ($M) | Net Loss ($M) | Adjusted EBITDA ($M) | Cash & Equiv. ($M) |
|---|---|---|---|---|---|---|---|
| 2025 | 1,271.8 | +83 | 955.4 | 316.4 | -245.0 | -7.4 | 609.5 |
| 2024 | 693.4 | +30 | 451.7 | 241.6 | -705.8 | -104.7 | 341.8 |
| 2023 | 531.8 | - | 363.0 | 168.8 | -214.1 | -154.2 | 166.6 |
Segment Performance: Diagnostics and Data & Applications (FY2023-FY2025)
| Fiscal Year | Diagnostics Revenue ($M) | Diagnostics Growth (%) | Diagnostics Test Volume | Hereditary Test Volume | Oncology Test Volume | Avg. Revenue per Oncology Test ($) | Data & Apps Revenue ($M) | Data & Apps Growth (%) |
|---|---|---|---|---|---|---|---|---|
| 2025 | 955.4 | +111 | 801,000 | 460,500 | 340,500 | 1,600 | 316.4 | +31 |
| 2024 | 451.7 | +24 | 270,800 | - | 270,800 | 1,510 | 241.6 | +43 |
| 2023 | 363.0 | - | - | - | - | 1,450 | 168.8 | - |
Data & Applications customer concentration: top 3 customers were 42% of segment revenue in FY2025 (three customers were 46% in FY2024).
Key Bullish and Bearish Points
| Bullish Points | Bearish Points |
|---|---|
| Explosive revenue growth (+83% YoY in FY2025) | Still unprofitable: net loss of $245M in FY2025 |
| Diagnostics scale-up via Ambry acquisition and hereditary test expansion | Heavy reliance on Diagnostics for majority of revenue (74% in FY2025) |
| Strong Data & Applications growth, with large pharma contracts (AstraZeneca, GSK, Recursion) | High customer concentration in Data & Applications (top 3 = 42% of segment) |
| Improving adjusted EBITDA, narrowing losses | Cash burn remains significant ($218M used in operations in FY2025) |
| Robust cash position ($609.5M at FY2025-end) after capital raises | Dilution risk from ATM equity, convertible notes, and stock-based comp |
| AI/ML leadership in diagnostics, digital pathology, and clinical trial matching | Regulatory and reimbursement risks remain high |
| International expansion (Japan JV) and new product launches | Integration risk from multiple acquisitions |
Positive and Negative Catalysts
| Positive Catalysts | Negative Catalysts |
|---|---|
| Further adoption of AI-enabled diagnostics and algorithms | Adverse changes in reimbursement or payer coverage |
| Expansion of pharma partnerships and data licensing deals | Delays or failures in integrating Ambry, Paige, Deep 6 |
| Successful international expansion (e.g., SB Tempus JV) | Regulatory setbacks (FDA, CLIA, GDPR, etc.) |
| New product launches in neuropsychiatry, cardiology, digital pathology | Increased competition in diagnostics/data platforms |
| Improved reimbursement rates for NGS and hereditary tests | Customer concentration risk in Data & Applications |
| Additional strategic M&A or technology partnerships | Litigation risk (e.g., ongoing Guardant Health lawsuits) |
Top Questions to Ask Before Investing
- Path to Profitability: What is the timeline and strategy for achieving sustained profitability, given ongoing net losses and cash burn?
- Diagnostics vs. Data Mix: How will the revenue mix evolve between Diagnostics and Data & Applications? Can Data & Applications become a larger share?
- Integration Execution: How is Tempus managing integration risk and realizing synergies from recent acquisitions (Ambry, Paige, Deep 6)?
- Reimbursement Risk: What are the key risks and opportunities in payer reimbursement for both oncology and hereditary testing?
- Customer Concentration: How dependent is Data & Applications revenue on a small number of large pharma clients? What is the renewal risk?
- AI/ML Differentiation: How defensible is Tempus’s AI/ML platform versus competitors (e.g., Foundation Medicine, Flatiron, Guardant, Caris)?
- Regulatory Environment: How could evolving FDA, CMS, and international regulations impact Tempus’s business model and product launches?
- International Strategy: What is the expected contribution and timeline for international expansion, especially the SB Tempus JV in Japan?
- Capital Allocation: How will Tempus deploy its substantial cash reserves and manage dilution from recent financings?
- Litigation Exposure: What is the potential financial and operational impact of ongoing and potential future litigation (e.g., Guardant Health)?
